As metastasis is what kills most cancer patients, it would seem this is where research would focus. But most cancer research today centers on the mobilization of the immune system to find and destroy cancer receptors in individual tumors, not stopping the spread. In Vivo covers Rgenix, an NY startup founded by three brothers who are prominent physician researchers. Rgenix already has a strong IP portfolio and aims to develop novel small molecule and antibody therapies to slow or eliminate disease progression in cancer patients for which there are limited or no alternative treatments. They have three investigational drug candidates moving into clinical trials.